NDAINTRAVENOUSSOLUTION
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CABAZITAXEL (cabazitaxel) by Accord Biopharma is inhibitor. Approved for prostate cancer, metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cabazitaxel is a microtubule-stabilizing taxane chemotherapy approved for metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It binds to tubulin and promotes microtubule assembly while inhibiting disassembly, leading to stabilization of microtubules and inhibition of cellular mitotic and interphase functions.
Peak
As a peak-stage product with moderate competitive pressure (30), the brand team is likely mid-sized and focused on maximizing formulary access and physician engagement in a crowded prostate cancer market.
Mechanism of Action
inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Worked on CABAZITAXEL at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.